ライフサイエンスコーパス: MSC

1 MSC infusions were well tolerated.

2 MSC interrupted binding of the TF GATA-3 to the locus en

3 MSC morphology after IFN-gamma stimulation significantly

4 MSC therapy improves cardiac function in animal models o

5 MSC-Ex recovered the destruction of the epithelial barri

6 MSC-Ex shifted the macrophage functional phenotype from

7 MSC-induced changes in macrophage phenotype critically d

8 MSCs also expressed mannose receptor (MR) that was found

9 MSCs can be grown in large numbers in vitro, and autolog

10 MSCs can respond to tissue injury by anti- or proinflamm

11 MSCs significantly decreased natural killer cells in the

12 MSCs suppressed cytokine production, increased M2 macrop

13 MSCs were fluorescently labeled and injected into a rat

14 MSCs were transfected with recombinant minicircles encod

15 In humans, a MSC subpopulation carrying markers for endothelial and p

16 Activated MSC were found to accumulate in the wound margins severa

17 eatment protocol was identified as activated MSC co-administered with antibiotic therapy.

18 r necrosis factor alpha (TNFalpha)-activated MSCs significantly promoted tumor growth.

19 2 and CXCL5) expressed by TNFalpha-activated MSCs efficiently recruited CXCR2(+) neutrophils into tum

20 ast cancer, we found that TNFalpha-activated MSCs strikingly enhanced tumor metastasis compared with

21 dispensable in supporting TNFalpha-activated MSCs to promote tumor metastasis.

22 on of the recipient immune response after AD-MSC treatment.

23 Although AD-MSC administration on POD 1 or POD 4, 8, and 15 resulted

24 timization of the dosing and frequency of AD-MSC therapy, either alone or used in, combination with o

25 the influence of timing and frequency of AD-MSC treatment on immunologic and graft survival as well

26 In addition, MSCs secreted nitric oxide after Mtb infection, and inhi

27 Because few intravenously administered MSCs engraft in the myocardium, studies have mainly util

28 Intravenously administered MSCs for acute myocardial infarction attenuate the progr

29 lar pathways through which IFN-gamma affects MSC plasticity and the consequence of their manipulation

30 hanced the immunosuppressive capacity of all MSC lines, and morphology predicted the magnitude of IFN

31 SCs/1 million CSCs, n = 7), 200 million allo-MSCs (n = 8), 1 million allo-CSCs (n = 4), or placebo (P

32 receive transendocardial injections of allo-MSCs + allo-CSCs (ACCT: 200 million MSCs/1 million CSCs,

33 Whereas allogeneic (allo-)MSCs are immunoevasive, the capacity of CSCs to similarl

34 andomized, controlled trial using allogeneic MSC, which are logistically more convenient than autolog

35 ardiac surgery, administration of allogeneic MSCs did not decrease the time to recovery of kidney fun

36 Although MSC-derived EVs (mEVs) are beneficial for acute lung inj

37 cells identifies in adult mouse synovium an MSC population largely negative for the skeletal stem ce

38 ffects of pFUS increased both MSC homing and MSC production of VEGF and IL-10, suggesting microenviro

39 tween left ventricular dysfunction (LVD) and MSC activation.

40 s model was established in C57BL/6 mice, and MSC-Ex was administered intraperitoneally.

41 timized seeding condition of NSCs, BMECs and MSCs.

42 ll cocultures of rat hippocampal neurons and MSCs.

43 Cotransplantation of NPIs and MSCs resulted in significantly earlier normoglycemia and

44 Transcriptomes of many diverse tissues and MSCs further show that lamin-A,C's increase with tissue

45 vidence of early AKI to receive intra-aortic MSCs (AC607; n=67) or placebo (n=68).

46 We armed MSCs with different oHSV variants (MSC-oHSV) and found t

47 )-purified Tbx18-expressing cells behaved as MSCs in vitro.

48 ith nonatherosclerotic-MSCs, atherosclerotic-MSCs displayed higher levels of both intracellular (P=0.

49 ive oxygen species levels of atherosclerotic-MSCs promoted a phenotypic switch characterized by enhan

50 ed mitochondrial function of atherosclerotic-MSCs underlies their altered secretome and reduced immun

51 Furthermore, treatment of atherosclerotic-MSCs with the reactive oxygen species scavenger N-acetyl

52 These results indicate that FOXP1 attenuates MSC senescence by orchestrating their cell-fate switch w

53 wn in large numbers in vitro, and autologous MSCs transfused into tuberculosis patients have been fou

54 ety of intra-arterial infusion of autologous MSCs in patients with RVD.

55 ignant cells through which crosstalk between MSCs and TGFbeta regulates tumour metastasis.

56 ry AML, and that IL8 was increased in AML/BM-MSC cocultures.

57 at bone marrow mesenchymal stromal cells (BM-MSC) protect AML blasts from spontaneous and chemotherap

58 Finally, targeted IL8 shRNA inhibited BM-MSC-induced AML survival.

59 cteristics with bone marrow-derived MSCs (BM-MSC).

60 novel interaction between AML blasts and BM-MSCs, which benefits AML proliferation and survival.

61 combinant MIF increased IL8 expression in BM-MSCs via its receptor CD74.

62 ta (PKCbeta) regulated MIF-induced IL8 in BM-MSCs.

63 human AML compared with AML cultured with BM-MSCs and found that macrophage migration inhibitory fact

64 nic transcription factors in normal jaw bone MSCs.

65 The molecular effects of pFUS increased both MSC homing and MSC production of VEGF and IL-10, suggest

66 red retrotransposition is much lower in both MSCs and HSCs when compared to NPCs.

67 Intra-arterial route is very promising, but MSCs are missing machinery for diapedesis through blood-

68 CL21 on inflammatory cells were inhibited by MSC-Exo.

69 Bacterial killing by MSC was found to be mediated in part by secretion of cat

70 s) in injured cortex were also attenuated by MSCs.

71 Protection by MSCs entails three complementary mechanisms: 1) internal

72 These cells (designated CAF-MSCs) enhanced in vitro neuroblastoma cell proliferation

73 dministration of activated allogeneic canine MSC.

74 nflammatory cytokines from activated cardiac MSCs of TLR4-deficient mice, compared with WT cardiac MS

75 improve LV remodeling and function, cardiac MSCs from LVD exacerbated anterior wall thinning 28 days

76 Although transplantation of cardiac MSCs and subcutaneous MSCs from LVD and sham hearts did

77 The inflammatory polarization of cardiac MSCs by LVD was mediated by TLR4, as we found less secre

78 ion of CD47 (don't eat me signal) on cardiac MSCs after both TLR4 stimulation in vitro and transplant

79 LVD switched cardiac MSCs toward an inflammatory phenotype, with increased se

80 T cardiac MSCs and saline, TLR4(-/-) cardiac MSCs survived in the cardiac tissue and maintained their

81 Next, we transplanted cardiac MSCs from TLR4(-/-) and WT male mice into the infarcted

82 Compared with WT cardiac MSCs and saline, TLR4(-/-) cardiac MSCs survived in the

83 LR4-deficient mice, compared with WT cardiac MSCs.

84 hils and inflammation, mucus-secreting cell (MSC) numbers, type 2-associated cytokines (interleukin (

85 IONALE: Virtually all mesenchymal stem cell (MSC) studies assume that therapeutic effects accrue from

86 Human mesenchymal stromal cell (MSC) lines can vary significantly in their functional ch

87 Mesenchymal stem cells (MSC) are currently employed for the treatment of inflamm

88 Mesenchymal stem cells (MSC) are promising therapeutics for critical limb ischem

89 Mesenchymal stem cells (MSC) exert antibacterial activity in vitro and in acute

90 Bone marrow-derived mesenchymal stem cells (MSC) have been promoted for multiple therapeutic applica

91 ne marrow-derived mesenchymal stromal cells (MSC) and in vitro 3T3-L1 preadipocytes significantly inc

92 Autologous mesenchymal stromal cells (MSC) treatments have shown feasibility, safety and stron

93 to originate from mesenchymal stromal cells (MSC), but their relationship with MSCs is not clear.

94 ne cells and mesenchymal stem/stromal cells (MSC).

95 Here we use mesenchymal system cells (MSC) as a potential substitute for pericytes in a BBB mo

96 sis and desensitizes mesenchymal stem cells (MSCs) against subsequent mechanical activation in vitro

97 tective potential of mesenchymal stem cells (MSCs) against the deleterious impact of AbetaOs on hippo

98 nation of autologous mesenchymal stem cells (MSCs) and cardiac stem cells (CSCs) synergistically redu

99 stem cells (iPSCs), mesenchymal stem cells (MSCs) and human umbilical vein endothelial cells (HUVECs

100 Here, mesenchymal stem cells (MSCs) and their nuclei spread in response to thickness-c

101 rogenitors and human mesenchymal stem cells (MSCs) appeared to contribute in replacement of 40% and 1

102 Bone marrow derived mesenchymal stem cells (MSCs) are regularly utilized for translational therapeut

103 tudies indicate that mesenchymal stem cells (MSCs) can stimulate angiogenesis and modify immune funct

104 he potential role of mesenchymal stem cells (MSCs) derived from human MT in the pathogenesis of bone

105 Adipose-derived (AD) mesenchymal stem cells (MSCs) especially have shown encouraging potential.

106 Human mesenchymal stem cells (MSCs) express scavenger receptors that internalize lipid

107 ment affects mesenchymal stromal/stem cells (MSCs) from umbilical cord's Wharton's Jelly (WJ) on a mo

108 Mesenchymal stem cells (MSCs) have multiple properties including anti-inflammato

109 of allogeneic human mesenchymal stem cells (MSCs) in reducing the time to recovery from AKI after ca

110 Mesenchymal stromal stem cells (MSCs) isolated from adult tissues offer tangible potenti

111 bone marrow-derived mesenchymal stem cells (MSCs) on SE-induced adverse changes.

112 Mesenchymal stem cells (MSCs) possess immunoregulatory, anti-inflammatory, and p

113 Mesenchymal stem cells (MSCs) represent promising resource of cells for regenera

114 ieved to function as mesenchymal stem cells (MSCs), multipotent tissue-resident progenitors with grea

115 ls (BMECs) and human mesenchymal stem cells (MSCs).

116 h to magnetize human mesenchymal stem cells (MSCs).

117 esis of human marrow mesenchymal stem cells (MSCs).

118 c differentiation of mesenchymal stem cells (MSCs).

119 Mesenchymal stromal cells (MSCs) are a promising candidate for a cell-based therapy

120 As mesenchymal stromal cells (MSCs) are continuously exposed in vivo to a dynamically

121 Mesenchymal stromal cells (MSCs) are one of major components of the tumour microenv

122 RATIONALE: Mesenchymal stromal cells (MSCs) are promising therapeutic strategies for coronary

123 BMF that Gli1(+) mesenchymal stromal cells (MSCs) are recruited from the endosteal and perivascular

124 (P10) aging human mesenchymal stromal cells (MSCs) could be used for bone tissue regeneration as tiss

125 from bone marrow mesenchymal stromal cells (MSCs) in vitro.

126 Mesenchymal stem/stromal cells (MSCs) play crucial roles in maintaining tissue homeostas

127 Mesenchymal stromal cells (MSCs) tend to infiltrate into tumors and form a major co

128 CM-MSC treatment reduces cartilage damage and suppresses im

129 CM-MSC treatment significantly reduced knee-joint swelling,

130 mesenchymal stem cell-conditioned medium (CM-MSC) as an alternative to cell therapy in an antigen-ind

131 In the presence of CM-MSC or MSCs, increases in IL-10 concentration were obser

132 from healthy mice following culture with CM-MSC or co-culture with MSCs.

133 ymph nodes of arthritic mice treated with CM-MSC or MSCs.

134 T cells from arthritic mice treated with CM-MSC showed increases in FOXP3 and IL-4 expression and po

135 ght multi-aminoacyl-tRNA synthetase complex (MSC), restricting the pool of free LysRS-tRNA(Lys) Mount

136 In contrast, CCL2 deficient MSCs did not induce T cell migration and VCAM-1 expressi

137 atopoietic stem cells or bone marrow-derived MSC or dendritic cells) for optimization of appropriate

138 hly suppressive human adipose tissue-derived MSC (AdMSC) display and induce a differential immunologi

139 ollowing transplantation of human BM-derived MSCs, globule-containing hepatocytes declined and donor-

140 regulated in the same manner in iPSC-derived MSCs.

141 nal characteristics with bone marrow-derived MSCs (BM-MSC).

142 ssessed the effect human bone marrow-derived MSCs have on neonatal porcine islets (NPIs) in vitro and

143 METHODS AND Adipose tissue-derived MSCs were isolated from atherosclerotic (n=38) and nonat

144 neering a variety of significantly different MSC shapes.

145 ogenesis RNA), by RNA interference disrupted MSC chondrogenesis, concomitant with reduced cartilage-s

146 ated the anti-arthritic effect of engineered MSCs in a collagen-induced arthritis (CIA) model.

147 or the delivery of biologics and engineering MSCs.

148 e from local myocardial effects of engrafted MSCs.

149 one outgrowth in MT, as mediated by enhanced MSC-driven osteogenic differentiation in the jaw bone.

150 In this study, GFP-MSCs were topically applied to the surface of cerebral c

151 Combined injection of sRAGE and hBD-MSCs resulted in enhanced survival of hBD-MSCs and angio

152 BD-MSCs resulted in enhanced survival of hBD-MSCs and angiogenesis in PIRI-CLI mice.

153 reactive T cells and helps to understand how MSCs ameliorate symptoms in lupus-prone MRL.Fas(lpr) mic

154 n umbilical cord mesenchymal stem cells (hUC-MSCs), originating in Wharton's jelly, are multipotent s

155 d 2 are robust new players involved in human MSC immunoregulatory mechanisms, and the higher suppress

156 the effect of local administration of human MSC-Exo on established EAU in the same species.

157 Ms) were cultured ex vivo with/without human MSC-derived EVs before adoptive transfer to LPS-injured

158 Human MSCs, grown chronically at 5% O2, were administered intr

159 n this study, we show that transfer of human MSCs increased MRL.Fas(lpr) mouse survival, decreased T

160 Together, these data identify MSC morphology as a predictive feature of MSC immunosupp

161 adiposity, decreased bone mass, and impaired MSC self-renewal capacity in mice.

162 er application, scientists sought to improve MSC functions by engineering.

163 e ligand 2 in the MSC secretome and improved MSCs immunosuppressive capacity (P=0.03).

164 ing drug effects will enable improvements in MSC therapies for renal disease.

165 n target of rapamycin (mTOR) manipulation in MSCs was studied in vivo in a mouse model of delayed-typ

166 Generating dysfunctional mitochondria in MSCs using rhodamine 6G pretreatment also abrogated thes

167 m memory keeper of the fibrogenic program in MSCs.

168 eases LBR:lamin-A,C protein stoichiometry in MSCs versus osteogenesis (stiff).

169 n synthesis in HEK293 cells only, whereas in MSCs, satisfactory results were obtained only after usin

170 theoretically produced from cells including MSCs.

171 Further, functionalization increased MSC adhesion to the surfaces and the alphavbeta3-selecti

172 Indeed, MSCs exhibited intrinsic autophagy, which was up-regulat

173 tes that extensive long-term culture-induced MSC aging impaired their osteogenic ability and subseque

174 of Notch signaling fully blocked OA induced MSC osteogenic differentiation.

175 ALF and tissue eosinophils and inflammation, MSC numbers, reduced the production of type 2 cytokines

176 Subsequently, we injected MSCs or saline into the infarcted myocardium of mice and

177 Intravenous MSCs eliminated the progressive deterioration in LV end-

178 of lung resident mesenchymal stem cells (LR-MSCs) and in the lung tissues of a pulmonary fibrosis mo

179 We have devised an adult human bone marrow MSC (hMSC) delivery formula by investigating molecular e

180 e test group received allogeneic bone marrow MSCs by intradiscal injection of 25 x 10 cells per segme

181 onditional depletion of Foxp1 in bone marrow MSCs led to premature aging characteristics, including i

182 In bone marrow MSCs, FOXP1 expression levels declined with age in an in

183 nd PTC MSCs were comparable with bone marrow MSCs.

184 On a stiff matrix, MSC cultured with conditioned media from mammary cancer

185 of allo-MSCs + allo-CSCs (ACCT: 200 million MSCs/1 million CSCs, n = 7), 200 million allo-MSCs (n =

186 ined whether administering extracts of MSCs (MSC-Ex) instead of MSCs could augment the beneficial eff

187 The effect of HA-coatings on murine MSC was functionally determined both, in vitro and in vi

188 Current methods to culture murine MSCs (mMSCs) select for rapidly dividing colonies and re

189 a (TGF-beta), we identified the TF musculin (MSC) as being critical for the development of induced Tr

190 hat upon HIV-1 infection, a free pool of non-MSC-associated LysRS is observed and partially relocaliz

191 Compared with nonatherosclerotic-MSCs, atherosclerotic-MSCs displayed higher levels of bo

192 hanced tumor metastasis compared with normal MSCs.

193 Only ACCT, but not MSCs or CSCs, prevented ongoing negative remodeling by o

194 nd found that intracarotid administration of MSC-oHSV, but not of purified oHSV alone, effectively tr

195 predicted the immunosuppressive capacity of MSC lines in a validation cohort.

196 ll immunosuppressive capacity in a cohort of MSC lines derived from different donors and manufacturin

197 melanoma brain metastasis, a combination of MSC-oHSV and PD-L1 blockade increases IFNgamma-producing

198 box P1 (FOXP1) in transcriptional control of MSC senescence.

199 al characteristics, and the effectiveness of MSC-based therapeutics may be realized by finding predic

200 MSCs could augment the beneficial effects of MSC therapy by overcoming the low homing efficiency of M

201 fy MSC morphology as a predictive feature of MSC immunosuppressive function.

202 n group (n=14) received a single infusion of MSC (1.0 x 10(5) or 2.5 x 10(5) cells/kg; n=7 each) plus

203 Loss of MSC reduced expression of the Treg cell master TF Foxp3

204 Our findings reveal a novel mechanism of MSC effects on malignant cells through which crosstalk b

205 Here, we aimed to determine the mechanism of MSC recruitment by Dendritic Cells (DC), hypothesising t

206 ent and increases the chances for success of MSC therapy in tissue-repair applications.

207 At 3 weeks after transplantation of MSC sheets, results showed more bony callus formed betwe

208 The protumorigenic activity of MSCs in vitro and in xenografted mice was dependent on t

209 esis is valid, intravenous administration of MSCs should improve outcomes in heart failure, an entity

210 ing the altered immunomodulatory capacity of MSCs in the context of atherosclerosis remain elusive.

211 r level, FOXP1 regulated cell-fate choice of MSCs through interactions with the CEBPbeta/delta comple

212 on offers a direct and efficient delivery of MSCs to the brain.

213 uired for the odontogenic differentiation of MSCs.

214 ion, promotes odontogenic differentiation of MSCs.

215 study, we focused on the paracrine effect of MSCs on macrophage polarization and the role of extracel

216 responsible for the pro-metastatic effect of MSCs since inhibition of this chemotaxis abolished incre

217 y by overcoming the low homing efficiency of MSCs systemically administered in inflammatory bowel dis

218 e examined whether administering extracts of MSCs (MSC-Ex) instead of MSCs could augment the benefici

219 stering extracts of MSCs (MSC-Ex) instead of MSCs could augment the beneficial effects of MSC therapy

220 efficient and minimally invasive methods of MSCs delivery to the brain still have to be developed.

221 changes from pFUS also increased potency of MSCs in situ to further enhance their efficacy.

222 the impaired immunomodulatory properties of MSCs from patients with atherosclerosis.

223 ly important in promoting the recruitment of MSCs to the site of skin injury, which in turn modulates

224 Following transfection of MSCs with the mms6 gene there is bio-assimilated synthes

225 This study thus demonstrates the utility of MSCs as OV carriers to disseminated brain lesions, and p

226 the hyaluronic acid (HA) receptor, CD44, on MSC membranes, to improve their homing potential towards

227 and the consequence of their manipulation on MSC functions.

228 ng is required for its osteogenic effects on MSCs.

229 In the presence of CM-MSC or MSCs, increases in IL-10 concentration were observed in

230 des of arthritic mice treated with CM-MSC or MSCs.

231 area of the chondriod callus in the aged P10 MSC sheet groups was significantly larger than in P3 MSC

232 bone ends in both young P3 MSC and aged P10 MSC sheet-wrapped groups when compared to allograft alon

233 t groups was significantly larger than in P3 MSC sheet groups.

234 llograft and host bone ends in both young P3 MSC and aged P10 MSC sheet-wrapped groups when compared

235 pFUS + MSC improved perfusion and vascular density in this clin

236 By 7 weeks post-treatment, pFUS + MSC significantly increased perfusion and CD31 expressio

237 %, demonstrating a prototype photoswitchable MSC.

238 slational progress has been hampered by poor MSC graft survival, jeopardizing cellular and molecular

239 EBVs fabricated from normal iSMCs or primary MSCs.

240 demonstrates that CCL2 enables the prolonged MSC-T cell interactions needed for sufficient suppressio

241 ry following cell culture expansion protects MSCs from fibrogenesis in the host wound environment and

242 tion characteristics of Thyroid MSCs and PTC MSCs were comparable with bone marrow MSCs.

243 Fluorescent and radiolabeled MSCs (1x10(6)) were injected 24 hours post-myocardial in

244 significance of BMP signaling in regulating MSC fate during root development and shed light on how B

245 mmary, our data show that CD34(+) derived SG-MSCs could be a promising cell source for adoptive cell-

246 f female WT mice and evaluated infarct size, MSC retention, inflammation, remodeling, and function af

247 splantation of cardiac MSCs and subcutaneous MSCs from LVD and sham hearts did not improve LV remodel

248 ine-filtering on-chip micro-supercapacitors (MSCs) based on coordination polymer frameworks were fabr

249 Finally, human synovial MSCs transduced with Bmp7 display morphogenetic properti

250 ARDS is a heterogeneous syndrome, targeting MSCs to patients with ARDS with a more hyperinflammatory

251 We found that MSC-Exo greatly reduced the intensity of ongoing EAU as

252 Interestingly, we found that MSC-produced CXCL12, an important chemokine in tumour me

253 Further experiments indicated that MSC contributed in a similar manner to pericytes in a co

254 Recent studies have shown that MSC tumour residence and their close interactions with i

255 lagen nanofilms serve as a model matrix that MSCs can easily deform unless the film is enzymatically

256 Results support the notion that MSCs may represent a promising alternative for cell-base

257 We report that MSCs phagocytose Mycobacterium tuberculosis (Mtb) throug

258 Time-lapse imaging revealed that MSCs recruited MRL.Fas(lpr) T cells establishing long-la

259 timuli, but how LysRS is redirected from the MSC to viral particles for packaging is unknown.

260 We first identified the MSC population supporting mouse molar root growth as Gli

261 tractant protein-1/chemokine ligand 2 in the MSC secretome and improved MSCs immunosuppressive capaci

262 tified by Pfirrmann grading, improved in the MSC-treated patients and worsened in the controls.

263 studies demonstrated that components of the MSC can be mobilized in response to certain cellular sti

264 Three days after topical application, the MSCs homed to the injured parenchyma and improved the ne

265 ytokeratin(+) cells in the bone marrow, this MSC subpopulation could prove useful in determining the

266 d differentiation characteristics of Thyroid MSCs and PTC MSCs were comparable with bone marrow MSCs.

267 the extracellular matrix (ECM) contribute to MSC phenotype in cancer remains poorly understood.

268 intravenously administered ischemia-tolerant MSCs (itMSCs) in patients with nonischemic cardiomyopath

269 Topical MSCs triggered earlier astrocytosis and reactive microgl

270 teogenic differentiation of mandibular torus MSCs was associated with the suppression of Notch3 signa

271 m contained only a small proportion of total MSCs.

272 omicroscopy as a novel imaging tool to track MSCs in vivo.

273 enous ITGA4-mRNA was detected in transfected MSCs.

274 myocardium drives resident and transplanted MSCs toward a proinflammatory phenotype and restricts th

275 ase in the migratory potential of HA-treated MSC compared to untreated cells.

276 This increased accumulation for HA-treated MSC yielded a substantial reduction in inflammation as d

277 However, the role of TNFalpha-treated MSCs in tumor metastasis remains elusive.

278 d efficacy of the intravenous infusion of UC-MSC in patients with chronic stable heart failure and re

279 Only the UC-MSC-treated group exhibited significant improvements in

280 UC-MSCs in vitro, compared with bone marrow-derived mesench

281 ized to intravenous infusion of allogenic UC-MSCs (Cellistem, Cells for Cells S.A., Santiago, Chile;

282 fe were observed in patients treated with UC-MSCs.

283 We armed MSCs with different oHSV variants (MSC-oHSV) and found that intracarotid administration of

284 In vitro, MSCs from individuals with coronary artery disease have

285 sults on histology demonstrate promises when MSCs are injected endotracheally (but not intravenously)

286 finding predictive features associated with MSC function.

287 US in mouse kidneys and its association with MSC tropism.

288 muscle actin, a marker of CAF, compared with MSC cultured on a soft matrix.

289 Adoptive transfer of AMs pretreated with MSC-derived EVs reduced inflammation and lung injury in

290 t with MSC-Ex was more potent than that with MSC in reducing DAI, the histological score, and nitrite

291 AMs treated with MSC-derived EVs ameliorate lung injury in vivo.

292 Treatment with MSC-Ex completely blocked the induction of inflammatory

293 Treatment with MSC-Ex was more potent than that with MSC in reducing DA

294 NPIs cocultured with MSCs had greater cellular insulin content and increased

295 owing culture with CM-MSC or co-culture with MSCs.

296 ch HE-iPSCs were separately co-cultured with MSCs and/or HUVECs.

297 mal cells (MSC), but their relationship with MSCs is not clear.

298 NPIs were cotransplanted with or without MSCs in diabetic B6.129S7-Rag1(tm1Mom)/J mice.

299 triple positive (CD73(+)CD90(+)CD105(+)) WJ MSCs found 67 genes with at least one CpG site where the

300 ody weight might bear consequences on the WJ MSCs.

301 e model similar to fresh passaged (P3) young MSCs.